Hiromichi Sakai

Dr. Hiromichi Sakai

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
FSFumio Sakane
Fumio Sakane
FHFumi Hoshino
Fumi Hoshino
MEMasayuki Ebina
Masayuki Ebina
HSHiromichi Sakai
Hiromichi Sakai
DTDaisuke Takahashi
Daisuke Takahashi
Diacylglycerol (DG) kinase (DGK) phosphorylates DG to generate phosphatidic acid (PA). The α isozyme is activated by Ca2+ through its EF-hand motifs and tyrosine phosphorylation. DGKα is highly expressed in several refractory cancer cells including melanoma, hepatocellular carcinoma, and glioblastoma cells. In melanoma cells, DGKα is an antiapoptotic factor that activates nuclear factor-κB (NF-κB) through the atypical protein kinase C (PKC) ζ-mediated phosphorylation of NF-κB. DGKα acts as an enhancer of proliferative activity through the Raf–MEK–ERK pathway and consequently exacerbates hepatocellular carcinoma progression. In glioblastoma and melanoma cells, DGKα attenuates apoptosis by enhancing the phosphodiesterase (PDE)-4A1–mammalian target of the rapamycin pathway. As PA activates PKCζ, Raf, and PDE, it is likely that PA generated by DGKα plays an important role in the proliferation/antiapoptosis of cancer cells. In addition to cancer cells, DGKα is highly abundant in T cells and induces a nonresponsive state (anergy), which represents the main mechanism by which advanced cancers escape immune action. In T cells, DGKα attenuates the activity of Ras-guanyl nucleotide-releasing protein, which is activated by DG and avoids anergy through DG consumption. Therefore, a DGKα-specific inhibitor is expected to be a dual effective anticancer treatment that inhibits cancer cell proliferation and simultaneously enhances T cell functions. Moreover, the inhibition of DGKα synergistically enhances the anticancer effects of programmed cell death-1/programmed cell death ligand 1 blockade. Taken together, DGKα inhibition provides a promising new treatment strategy for refractory cancers.

23 May 2014 in Lipids
Verified
Journal Article
Closed access
PDF file
SSShizuka Sakiyama
Shizuka Sakiyama
TUTakako Usuki
Takako Usuki
HSHiromichi Sakai
Hiromichi Sakai
FSFumio Sakane
Fumio Sakane

2 December 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
AAAbul Kalam Azad
Abul Kalam Azad
ASAbdullah Sheikh
Abdullah Sheikh
AHAhsanul Haque
Ahsanul Haque
HOHarumi Osago
Harumi Osago
HSHiromichi Sakai
Hiromichi Sakai
ANAtsushi Nagai
Atsushi Nagai
Plasmalogens are alkenyl-acyl glycerophospholipids and decreased in post-mortem Alzheimer’s disease (AD) brains. The aim of this study is to investigate the time-dependent changes of plasmalogens in the hippocampus of an AD model mouse (J20). Plasmalogen levels at 3, 6, 9, 12 and 15 months were analyzed by liquid-chromatography-targeted-multiplexed-selected-reaction-monitoring-tandem-mass-spectrometry (LC-SRM/MS). Reactive oxygen species (ROS) levels were evaluated using dichlorofluorescein diacetate (DCF-DA). Plasmalogen synthesizing enzyme glycerone-phosphate O-acyltransferase (GNPAT) and late endosome marker Rab7 levels were quantified by Western blotting. GNPAT localization, changes of neuronal and glial cell numbers were evaluated by immunostaining. Compared to wild-type mice (WT), total plasmalogen-ethanolamine, but not plasmalogen-choline levels, were increased at 9 months and subsequently decreased at 15 months in J20 mice. A principal component analysis of plasmalogen-ethanolamine species could separate WT and J20 mice both at 9 and 15 months. Both GNPAT and Rab7 protein were increased in J20 mice at 9 months, whereas GNPAT was decreased at 15 months. ROS levels were increased in J20 mice except for 9 months. Our results suggest that increased plasmalogen-ethanolamine could counteract ROS levels and contribute to the phagocytosis process in J20 mice at 9 months. Such results might indicate a transient protective response of plasmalogen-ethanolamine in AD conditions.

1 October 2020 in Biochimie
Verified
Journal Article
Closed access
HSHiromichi Sakai
Hiromichi Sakai
Chiaki MurakamiChiaki Murakami
Chiaki Murakami
TUTakako Usuki
Takako Usuki
QLQiang Lu
Qiang Lu
KMKen-Ichi Matsumoto
Ken-Ichi Matsumoto
FSFumio Sakane
Fumio Sakane

27 July 2022 in FEBS Open Bio
Verified
Journal Article
Open access
HSHiromichi Sakai
Hiromichi Sakai
KMKen‐Ichi Matsumoto
Ken‐Ichi Matsumoto
TUTakeshi Urano
Takeshi Urano
FSFumio Sakane
Fumio Sakane
Effective amelioration of type II diabetes requires therapies that increase both glucose uptake activity per cell and skeletal muscle mass. Myristic acid (14:0) increases diacylglycerol kinase (DGK) δ protein levels and enhances glucose uptake in myotubes in a DGKδ‐dependent manner. However, it is still unclear whether myristic acid treatment affects skeletal muscle mass. In this study, we found that myristic acid treatment increased the protein level of β‐tubulin, which constitutes microtubules and is closely related to muscle mass, in C2C12 myotubes but not in the proliferation stage in C2C12 myoblasts. However, lauric (12:0), palmitic (16:0) and oleic (18:1) acids failed to affect DGKδ and β‐tubulin protein levels in C2C12 myotubes. Moreover, knockdown of DGKδ by siRNA significantly inhibited the increased protein level of β‐tubulin in the presence of myristic acid, suggesting that the increase in β‐tubulin protein by myristic acid depends on DGKδ. These results indicate that myristic acid selectively affects β‐tubulin protein levels in C2C12 myotubes via DGKδ, suggesting that this fatty acid improves skeletal muscle mass in addition to increasing glucose uptake activity per cell.

1 November 2017 in Neuroscience Research
Verified
Journal Article
Closed access
HSHiromichi Sakai
Hiromichi Sakai
SYShigefumi Yokota
Shigefumi Yokota
NKNaoyo Kajitani
Naoyo Kajitani
TYTsunao Yoneyama
Tsunao Yoneyama
KKKohei Kawakami
Kohei Kawakami
KMKen-Ichi Matsumoto
Ken-Ichi Matsumoto